Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL) [Combinazione Rituximab-Bendamustina per il trattamento di I linea in soggetti anziani (≥70 anni) "fragili" affetti da Linfoma non Hodgkin a grandi cellule B: studio multicentrico di fase II della Fondazione Italiana Linfomi (FIL)]

Trial Profile

Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL) [Combinazione Rituximab-Bendamustina per il trattamento di I linea in soggetti anziani (≥70 anni) "fragili" affetti da Linfoma non Hodgkin a grandi cellule B: studio multicentrico di fase II della Fondazione Italiana Linfomi (FIL)]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms R-BENDA frail study
  • Most Recent Events

    • 09 Dec 2014 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01990144).
    • 07 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top